WESTMINSTER, Colo.--(BUSINESS WIRE)--Oct. 26, 2009--
Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company
committed to the development and commercialization of innovative
anti-cancer therapeutics, today announced that Company management will
provide a corporate update and review of the third quarter 2009 results
via webcast and conference call on Tuesday, November 3, 2009, at 4:30
p.m. ET.
To access the live audio webcast or the subsequent archived recording,
visit the “Investors - Presentations and Events” section of the
Company’s website at www.allos.com.
Alternatively, callers may participate in the conference call by dialing
1-877-941-8610 (domestic) or 480-629-9819 (international). Participants
should reference the Allos Therapeutics conference call. Webcast and
telephone replays of the conference call will be available approximately
two hours after the completion of the call through Friday, November 13,
2009. To access the replay, callers should dial 1-800-406-7325
(domestic) or 303-590-3030 (international) and use passcode 4169927#.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical company
committed to the development and commercialization of innovative
anti-cancer therapeutics. Allos is currently focused on the development
and commercialization of FOLOTYNTM (pralatrexate injection),
a folate analogue metabolic inhibitor. FOLOTYN is the first and only
drug approved in the U.S. for the treatment of patients with relapsed or
refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN
in other potential indications. Allos retains exclusive worldwide rights
to FOLOTYN for all indications. Allos is headquartered in Westminster,
CO. For additional information, please visit www.allos.com.
Safe Harbor Statement
The 2009 third quarter results press release and conference call will
contain forward-looking statements that involve significant risks and
uncertainties, including those contained in the "Risk Factors" section
of the company's Form 10-Q for the quarter ended June 30, 2009 and in
the company's other periodic reports and filings with the Securities and
Exchange Commission. Allos is providing the information contained in the
press release and conference call as of the date of the release and does
not undertake any obligation to update any forward-looking statements as
a result of new information, future events or otherwise. The Company
cautions investors not to place undue reliance on the forward-looking
statements contained in the press release or the conference call. No
forward-looking statement can be guaranteed and actual events and
results may differ materially from those projected.
Source: Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
mgreer@allos.com
